Stevia Sweetener Triggers Release of Appetite-Regulating Peptides GLP-1 and PYY from Gut Cells | Research

The takeaway

The stevia sweetener rebaudioside A stimulated GLP-1 release up to 4.3-fold and PYY release 3-fold from mouse intestinal organoids, suggesting potential metabolic benefits beyond zero calories.

4.3-fold GLP-1 increase in ileum
Rebaudioside A stimulated GLP-1 release most strongly in the lower small intestine (ileum), where L-cells naturally concentrate — suggesting a physiologically relevant site of action.

What the researchers found

The stevia-derived sweetener rebaudioside A dramatically increased GLP-1 peptide release from mouse intestinal organoids: 1.7-fold in duodenum (p<0.01), 2.2-fold in jejunum (p<0.01), and 4.3-fold in ileum (p<0.001). It also increased PYY release 3-fold in the ileum (p<0.05). Long-term (18-hour) exposure increased expression of enteroendocrine cell markers: chromogranin A 3.5-fold, glucagon 3.5-fold, PYY 3.8-fold, and CCK 6.5-fold (all p<0.05 or better), suggesting rebaudioside A not only stimulates peptide secretion but also promotes enteroendocrine cell differentiation.

Why it matters

GLP-1 is the target of blockbuster diabetes and obesity drugs like semaglutide. This study suggests that a common zero-calorie sweetener can naturally stimulate GLP-1 and PYY release from gut cells. If confirmed in humans, this could mean stevia-based sweeteners have metabolic benefits beyond simply replacing sugar — they might actively promote the release of appetite-regulating and insulin-stimulating peptides.

The numbers in context

GLP-1: 1.7-fold (duodenum), 2.2-fold (jejunum), 4.3-fold (ileum) · PYY: 3-fold (ileum) · chromogranin A: 3.5-fold · glucagon: 3.5-fold · PYY gene: 3.8-fold · CCK: 6.5-fold · 10 mmol/L rebaudioside A · 1h and 18h stimulation

How the study worked

Researchers developed 2D organoids from mouse duodenal, jejunal, and ileal intestinal crypts. Organoids were characterized by gene expression and immunofluorescence, confirming the presence of enteroendocrine cells positive for GLP-1, PYY, and serotonin. Organoids were stimulated with 10 mmol/L rebaudioside A for 1 hour (secretion) or 18 hours (gene expression), and GLP-1, PYY, and CCK release and gene expression were measured.

Who was studied

2D intestinal organoids derived from C57BL/6J mouse duodenal, jejunal, and ileal crypts

What this study cannot tell us

This is an ex vivo mouse organoid study — results may not translate to intact intestine or human physiology. The 10 mmol/L rebaudioside A concentration may be higher than physiologically achieved from dietary stevia consumption. The organoid model lacks the nervous system and blood supply that influence hormone secretion in vivo. Whether increased enteroendocrine marker expression translates to actual cell number increase was not definitively confirmed.

How to read the evidence

This is a preclinical ex vivo study using mouse intestinal organoids. The model system is well-characterized and appropriate for studying hormone secretion, but the findings need validation in intact animal models and human studies before drawing conclusions about dietary stevia consumption.

When this study was published

Published in 2016, this study provides early evidence for stevia's effects on gut peptide hormones. Subsequent research has continued to explore how sweeteners affect the enteroendocrine system.

The bigger picture

In the era of GLP-1 receptor agonist drugs generating billions in revenue, the finding that a common dietary sweetener can stimulate endogenous GLP-1 release is intriguing. While the effect would be far smaller than pharmacological GLP-1 RA doses, it suggests that dietary choices can influence the same peptide hormone pathways. This connects the rapidly growing field of gut peptide therapeutics to nutritional science and the ongoing debate about artificial sweetener safety.

Questions still open

Does consuming stevia-sweetened foods increase circulating GLP-1 and PYY levels in humans?
Could rebaudioside A be combined with GLP-1 receptor agonists to enhance their metabolic effects?
Is the GLP-1-stimulating effect of stevia part of the reason some studies show metabolic benefits from zero-calorie sweeteners?

Common questions

Does this mean drinking stevia-sweetened beverages will have the same effect as taking semaglutide?

No — the effects would be dramatically different in magnitude. Semaglutide is a drug that continuously activates GLP-1 receptors at high levels for days. The GLP-1 release triggered by stevia in this study, even if it occurs in humans, would be a brief, small natural pulse. However, it's interesting that a common sweetener can stimulate the same peptide pathway, and regular consumption could potentially contribute to modest metabolic benefits.

Why was GLP-1 release highest in the ileum?

The ileum (lower small intestine) contains the highest concentration of L-cells, which are the specialized enteroendocrine cells that produce and release GLP-1. This is also where rebaudioside A showed the strongest stimulatory effect (4.3-fold), suggesting the sweetener preferentially activates the gut region most equipped to produce this appetite-regulating peptide.

Read the original research

The Noncaloric Sweetener Rebaudioside A Stimulates Glucagon-Like Peptide 1 Release and Increases Enteroendocrine Cell Numbers in 2-Dimensional Mouse Organoids Derived from Different Locations of the Intestine.

The Journal of nutrition, 146(12), 2429-2435

View on PubMed ↗

Citation

van der Wielen, Nikkie; Ten Klooster, Jean Paul; Muckenschnabl, Susanne; Pieters, Raymond; Hendriks, Henk Fj; Witkamp, Renger F; Meijerink, Jocelijn. (2016). The Noncaloric Sweetener Rebaudioside A Stimulates Glucagon-Like Peptide 1 Release and Increases Enteroendocrine Cell Numbers in 2-Dimensional Mouse Organoids Derived from Different Locations of the Intestine.. The Journal of nutrition, 146(12), 2429-2435.